The safety and efficacy of adipose tissue-derived exosomes in treating mild to moderate plaque psoriasis: A clinical study.
Mohseni Meybodi MA., Nilforoushzadeh MA., KhandanDezfully N., Mansouri P.
Prospective Study with a reported sample of 12 on Chronic Inflammation, published in Life Sci (2024) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Life Sci (2024)
- Country
- Netherlands
- Reported sample size
- 12
- Source database
- PubMed
- PMID
- 39013528
- DOI
- 10.1016/j.lfs.2024.122915
Abstract (original English)
This study evaluates the safety and efficacy of autologous adipose-derived mesenchymal stem cell-derived exosomes as a treatment for Psoriasis, a chronic immune-related skin and joint disorder, compared to current treatments like topicals, phototherapy, and systemic. The study isolated exosomes from Mesenchymal Stem Cells(MSCs) of healthy adipose tissue using ultracentrifugation. 12 patients with plaque psoriasis were divided into three groups and given single doses of exosomes. Tissue samples were collected pre- and post-treatment and examined for inflammatory(TNFα, IL23, IL17, IFNγ, CD3) and anti-inflammatory (FOXP3, IL10) markers. The severity of the lesion was also evaluated. In this study, it was found that erythema and induration (P < 0.05) decreased significantly in patients receiving 200 μg. Still, this reduction in scaling was not significant, the thickness was significantly reduced in patients receiving 100 and 200 μg doses (P < 0.05). H&E evaluation showed that the decreasing trend in these patients was not significant (P > 0.05). IHC evaluation in patients receiving doses of 100 and 200 μg showed a decrease in the presence of IL17 (P < 0.05, <0.001) & CD3(P < 0.001, <0.05) and a considerable increase in FOXP3(P ≤ 0.001), in the tissue samples of the patients. Examining the expression of inflammatory factors also shows that dose 200 μg decreased the expression of IL1
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Comparing Regenerative Biologics and Standard Pharmacotherapy for Chronic Rotator Cuff Tendinopathy: A Study of PRP, Cell-Based, and Peptide Interventions
Systematic Review on Tendon Injury, Rotator Cuff, Shoulder Pain, Chronic Inflammation, published in J Orthop Sports Med (2026) — summary generated from the PubMed abstract.
- 2026
J Orthop Sports Med - Level ASystematic ReviewEurope PMC
Harnessing exosomes in dry eye disease: a triple threat approach
Systematic Review on Neuroinflammation, Chronic Inflammation, Immune Modulation, published in BMC Ophthalmol (2026) — summary generated from the PubMed abstract.
- 2026
BMC Ophthalmol - Level AMeta-analysisPubMed
Comparative efficacy of different doses of mesenchymal stem cells derived from different tissue sources for knee osteoarthritis: a systematic review and network meta-analysis of randomized controlled trials.
Meta-analysis with a reported sample of 602 on Knee Osteoarthritis, Osteoarthritis, Chronic Inflammation, Immune Modulation, published in PeerJ (2026) — summary generated from the PubMed abstract.
- 2026
- n = 602
PeerJ - Level ASystematic ReviewEurope PMC
Exosomes as Cellular Communicators and Therapeutic Agents in Orthopedic Diseases: From Mechanisms to Intervention
Systematic Review on Osteoarthritis, Chronic Inflammation, published in Int J Nanomedicine (2026) — summary generated from the PubMed abstract.
- 2026
Int J Nanomedicine1 citations - Level ASystematic ReviewEurope PMC
Pharmacotherapy agents in prevention and treatment of breast cancer-related lymphedema: a systematic scoping review
Systematic Review on Chronic Inflammation, Immune Modulation, published in Front Oncol (2026) — summary generated from the PubMed abstract.
- 2026
Front Oncol - Level ASystematic ReviewEurope PMC
Trends in peripheral nerve injury research: a bibliometric analysis focused on molecular mechanisms
Systematic Review on Chronic Inflammation, published in Front Neurol (2026) — summary generated from the PubMed abstract.
- 2026
Front Neurol